Emerging preclinical and clinical profile of 311C90: A poster review and discussion

被引：3

作者：

Ferrari, MD

Martin, GR

Earl, NL

Klein, KB

机构：

来源：

EUROPEAN NEUROLOGY | 1996年 / 36卷

关键词：

311C90; receptor specificity; vasoconstriction; antiemetic effects; trigemino-vascular system; clinical pharmacology; efficacy; safety; quality of life;

D O I：

10.1159/000119099

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：19 / 23

页数：5

共 23 条

[1]

Dixon R, 1995, CEPHALALGIA S14, V15, P218

[2]

DIXON R, 1995, HEADACHE, V35, P304

[3] Clinical safety of 311C90: Aggregated data from patients and volunteers to date [J].

Earl, NL .

EUROPEAN NEUROLOGY, 1996, 36 :8-12

[4]

FERRARI MD, 1996, EUR NEUROL S2, V36, P47

[5]

GIORGI L, 1995, CEPHALALGIA S14, V15, P220

[6]

GLEN RC, 1994, HEADACHE, V34, P307

[7] PERIPHERAL AND CENTRAL TRIGEMINOVASCULAR ACTIVATION IN CAT IS BLOCKED BY THE SEROTONIN (5HT)-1D RECEPTOR AGONIST 311C90 [J].

GOADSBY, PJ ;

EDVINSSON, L .

HEADACHE, 1994, 34 (07) :394-399

[8]

GOADSBY PJ, 1995, CEPHALALGIA S14, V15, P106

[9]

Hill AP, 1994, HEADACHE, V34, P308

[10]

KNIGHT YE, 1995, CEPHALALGIA S14, V15, P214

← 1 2 3 →